BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25332440)

  • 1. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
    Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
    Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
    J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer.
    Jentzen W; Verschure F; van Zon A; van de Kolk R; Wierts R; Schmitz J; Bockisch A; Binse I
    J Nucl Med; 2016 Oct; 57(10):1499-1504. PubMed ID: 27199362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
    Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
    Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 124I-PET/CT images of differentiated thyroid cancer patients. Distinguishing lymph node metastases from thyroid remnants using kinetic quantities.
    Rosenbaum-Krumme S; Nagarajah J; Ruhlmann M; Bockisch A; Jentzen W
    Nuklearmedizin; 2012; 51(6):213-6. PubMed ID: 22892653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
    J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
    Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study.
    Ilhan H; Mustafa M; Bartenstein P; Kuwert T; Schmidt D
    Nuklearmedizin; 2016 Dec; 55(6):221-227. PubMed ID: 27588323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
    Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
    Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.
    Nagarajah J; Jentzen W; Hartung V; Rosenbaum-Krumme S; Mikat C; Heusner TA; Antoch G; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1862-8. PubMed ID: 21739331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
    Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
    Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
    Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
    J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
    O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
    Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.